Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Immunovia Provides an Update on its Lung Cancer Pipeline Projects

October 2, 2019

LUND, SWEDEN – Immunovia AB (publ) (“Immunovia”) today announced that progress has been steady and continuous with its lung cancer projects.  As previously announced, Immunovia completed a test study in 2018 in collaboration with a global pharmaceutical partner. In this small study, Immunovia ́s IMMray™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) with an 95% accuracy (link to PR). The results demonstrated that IMMray™ has the potential to become a benchmark platform for early diagnosis of cancer diseases beyond the company’s first indication, pancreatic cancer.

These positive results have progressed into two company opportunities, leading to a broader collaboration with the global pharmaceutical company, as well as the initiation of Immunovia’s own studies on early detection of lung cancer.

Update on Collaboration with Immunovia’s Global Pharma Partner:

The scope of this on-going collaboration, set by our pharma partner, is to test for responders vs. non-responders for their drugs targeting lung cancer. The key elements are that the project continues to have a positive progression, and the ultimate focus remains to predict response to drug treatments. Furthermore, in the short term, the ongoing second study will be further expanded with additional freshly collected blood samples, to be provided by the Pharma partner, to validate the statistics. Additionally, this extended study will benefit Immunovia’s early detection program.

Update on Immunovia’s Early Detection of Lung Cancer Studies:

The scope of these studies is to evaluate Immunovia’s IMMray™ platform technology in developing commercial tools for early diagnosis of lung cancer. Immunovia has identified two target areas within early diagnostics of lung cancer testing that the company will now focus on. These areas can have a significant impact on improved outcomes for patients:

    • Early detection in stage I & II of NSCLC
    • Differentiation between true positives and false positives after low dosage CT screening of high-risk patients

Immunovia has commenced building the Key Opinion Leader (KOL) network that will be the source of fresh, high quality blood samples for the various testing phases required to bring the test to the market. First blood sample delivery from the KOL network within early NSCLC detection will be in Q4 2019.  

“The progress with our pharma collaboration has moved somewhat slower than originally anticipated. However, steady progress is being made and we remain very positive with this joint effort,” stated Mats Grahn, CEO of Immunovia. Mr. Grahn continued, “Regarding our own study to test our IMMray™ platform for early detection of lung cancer, we have moved full-speed ahead to build the key opinion leader network and to obtain the necessary samples to initiate our own retrospective studies.  We now look forward to providing updates as we make more progress with both our own studies as well as about the collaboration with our pharma partner.”

For more information, please contact:
Julie Silber
Director of Investor Relations
Tel: +46 7 93 486 277

This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 CET on October 2, 2019.

About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit


Immunovia Press Release